Evidence map›Paper›PMID 35394838›Full record

ArticleScience advances2022

Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.

Abigail K Grosskopf, Louai Labanieh, Dorota D Klysz, Gillie A Roth, Peng Xu, Omokolade Adebowale, Emily C Gale, Carolyn K Jons, John H Klich, Jerry Yan and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 222 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Biomaterial-EnabledCell biomaterials · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Abigail K GrosskopfDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-0471-1825
Louai LabaniehDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-3998-7415
Dorota D KlyszCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6733-6110
Gillie A RothDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-3451-3694
Peng XuCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Omokolade AdebowaleDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.
Emily C GaleDepartment of Biochemistry, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6536-3027
Carolyn K JonsDepartment of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-2322-6726
John H KlichDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-9285-1018
Jerry YanDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-8278-1354
Caitlin L MaikawaDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6214-1226
Santiago CorreaDepartment of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-8230-4945
Ben S OuDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-0539-5166
Andrea I d'AquinoDepartment of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-4204-8219
Jennifer R CochranDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6532-9873
Ovijit ChaudhuriDepartment of Mechanical Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-9287-3401
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0359-9023
Eric A AppelDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-2301-7126
Stanford University · USPalo Alto Institute · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Role of extracellular matrix malleability in mediating breast cancer cell invasion and migrationR37CA214136 · NCI · STANFORD UNIVERSITY · PI CHAUDHURI, OVIJIT · 2018 to 2024
$2.5M
Cancer immunotherapy using injectable hydrogels for precise and tunable multidrug deliveryF32CA247352 · NCI · STANFORD UNIVERSITY · PI CORREA, SANTIAGO · 2020 to 2022
$201k
Role of Matrix Viscoelasticity on Tumor-Macrophage InteractionsF31CA250405 · NCI · STANFORD UNIVERSITY · PI ADEBOWALE, KOLADE · 2020 to 2021
$54k
NCI NIH HHS F31 CA250405NCI NIH HHS F32 CA247352NCI NIH HHS P30 CA124435NCI NIH HHS R37 CA214136NIGMS NIH HHS T32 GM007276
6 · The paper itself

Abstract

Adoptive cell therapy (ACT) has proven to be highly effective in treating blood cancers, but traditional approaches to ACT are poorly effective in treating solid tumors observed clinically. Novel delivery methods for therapeutic cells have shown promise for treatment of solid tumors when compared with standard intravenous administration methods, but the few reported approaches leverage biomaterials that are complex to manufacture and have primarily demonstrated applicability following tumor resection or in immune-privileged tissues. Here, we engineer simple-to-implement injectable hydrogels for the controlled co-delivery of CAR-T cells and stimulatory cytokines that improve treatment of solid tumors. The unique architecture of this material simultaneously inhibits passive diffusion of entrapped cytokines and permits active motility of entrapped cells to enable long-term retention, viability, and activation of CAR-T cells. The generation of a transient inflammatory niche following administration affords sustained exposure of CAR-T cells, induces a tumor-reactive CAR-T phenotype, and improves efficacy of treatment.

Indexed as

NeoplasmsReceptors, Chimeric AntigenCytokinesHumansHydrogelsImmunotherapy, AdoptiveT-LymphocytesCytokinesHydrogelsReceptors, Chimeric Antigen

Identifiers

PMID35394838
PMCPMC8993118
OpenAlexW4226203376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.